Kinectic Games has released the latest major update for horror game Phasmophobia, and this time, it brings the much-anticipated 6 Tanglewood Drive rework. Tagged by the developers as v016.00, console ...

Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...

Immigration officials are testifying before the House Homeland Security Committee on Tuesday for the first time since two U.S. citizens were killed in the recent immigration crackdown in Minneapolis.

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

Google Warns Over 1 Billion Android Phones Are Now at Risk Your email has been sent If you’re using an older Android phone, Google has a message you probably don’t want to hear. More than 40% of ...

The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) ­— a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...

FDA labeling now permits axi-cel use in R/R PCNSL, making it the first CAR T for R/R LBCL with CNS lymphoma limitations removed. Phase 1 Dana-Farber study (N=18; PCNSL n=13) prioritized ...

– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Primary central nervous system lymphoma is ...

WASHINGTON, D.C. — Diabetes patients who use certain TRUE METRIX blood glucose meters are being urged to review updated safety instructions after manufacturer ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

(RTTNews) - Kite, a Gilead Company (GILD), announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relapsed or refractory ...